PRPF19

Across TCGA pan-cancer cohorts, PRPF19 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PRPF19 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher PRPF19 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRPF19 expression acts as an unfavorable survival marker, although some lineages such as COAD and LSCC show a favorable association.

COAD, LSCC, and UCEC are the cancer types where PRPF19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	1.000	0.889	.024	18	view →
LSCC	DFS	Tertile	All	0.870	0.627	.013	11	view →
UCEC	DFS	Median	All	0.933	1.000	.015	10	view →
HNSC	OS	Median	All	0.785	0.901	.011	7	view →
LUAD	OS	Median	II,III,IV	0.871	0.463	.020	6	view →
PDAC	DFS	Quartile	III,IV	0.268	0.518	.021	4	view →
GBM	DFS	Median	All	0.403	0.237	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PRPF19–COAD (DFS)

Open the COAD breakdown →